SEC Form 4 · accession 0001193125-26-261672

TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 5, 2026

Accepted (ET)

Jun 8, 2026 · 4:02 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0000818686

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1,F2	Jun 5, 2026	M	14,492	—	A	119,807	D
Ordinary Shares^F1,F3	holding	—	—		—	367,600	I	[see footnote]

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2,F4,F1	—	Jun 5, 2026	M	14,492	D	—	—	Ordinary Shares	14,492	0	D

F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3The 367,600 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.
F4Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.